Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Hong-Ju Tian"'
Publikováno v:
BMC Pregnancy and Childbirth, Vol 22, Iss 1, Pp 1-7 (2022)
Abstract Background To investigate the safety and effectiveness of tubal inflammatory drugs in patients with incomplete tubal obstruction of at least one side after four-dimensional hysterosalpingo-contrast-sonography (4D-HyCoSy) examination. Methods
Externí odkaz:
https://doaj.org/article/9f2e93a34fa14501bfad5368d5a6e5e9
Background To investigate the safety and effectiveness of tubal inflammatory drugs in patients with incomplete tubal obstruction of at least 1 side after four-dimensional hysterosalpingo-contrast-sonography (4D-HyCoSy) examination. Methods 215 cases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f42a7439310aa6930a34a0efe607914
https://doi.org/10.21203/rs.3.rs-1084331/v1
https://doi.org/10.21203/rs.3.rs-1084331/v1
Publikováno v:
BMC pregnancy and childbirth. 22(1)
Background To investigate the safety and effectiveness of tubal inflammatory drugs in patients with incomplete tubal obstruction of at least one side after four-dimensional hysterosalpingo-contrast-sonography (4D-HyCoSy) examination. Methods Two hund
Autor:
Zhengqiong Chen, Shu-Yu Long, Na Kuang, Ping Yan, Hong-Ju Tian, Zhi-Jia Zhang, Li Luo, Xi Xiong, De-Mei Ying, Chun-Yan Gao
Publikováno v:
Contrast Media & Molecular Imaging
Contrast Media & Molecular Imaging, Vol 2020 (2020)
Contrast Media & Molecular Imaging, Vol 2020 (2020)
Purpose. The effect of mifepristone for treatment of low-risk cesarean scar pregnancy (CSP) was monitored by contrast-enhanced ultrasound (CEUS). Methods. Data were collected from 23 CSP patients with a 10-point risk score p values >0.05). There was
Publikováno v:
Journal of Central South University. 20:3379-3384
Three new ferrocene (Fc) based receptors with pyridyl moiety, named methyl-6-ferrocenoylacetyl-2-pyridine carboxylate (FcL1), 1,1′-(2,6-bispyridyl)bis-3-ferrocenyl-1,3-propanedione (FcL2), ferrocenecarboxaldehyde-2,6-dipicolinoyhydrazone (FcL3) wer